Member Info for Hurst10

POINT Biopharma Debuts as Publicly Traded
Next-Generation Radiotherapeutics Company
Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol ?PNT?
Gross proceeds from the transaction totaled approximately $286.7 million

Avacta?s JV partner

More interesting is that Innova sent letters to the users and demanding they sent the tests back!
On April 23, 2021, Innova Medical Group sent all affected device users an Urgent Medical Device Recall letter. The letter provided the following information:
Do not use these tests to screen for or diagnose COVID-19.
Identify and remove all affected tests from inventory.
Either destroy the tests by placing them in the trash or return the tests using the FedEx return label that was included with the letter Innova sent to its customers.
Complete and return the form Innova sent to its customers, indicating the number of destroyed or returned tests.

From the FDA web site
:
Ref Innova SARS-CoV-2 Antigen Rapid Qualitative Test.
Manufacturing Dates: September 1, 2020 to March 3, 2021
Distribution Dates: November 2, 2020 to March 22, 2021
Devices Recalled in the U.S.: At least 77,339
Date Initiated by Firm: March 24, 2021

Reason for Recall
Innova Medical Group is recalling its SARS-CoV-2 Antigen Rapid Qualitative Test. Labeling distributed with certain configurations of the test includes performance claims that did not accurately reflect the performance estimates observed during the clinical studies of the tests. The performance characteristics of the test have not been adequately established, presenting a risk of false results.
False-negative results may lead to delayed diagnosis or inappropriate treatment of SARS-CoV-2, which may cause patient harm including serious illness and death. False-negative results can also lead to further spread of the SARS-CoV-2 virus, including when presumed negative patients are grouped into cohorts in health care, long-term care, and other facilities based on false test results.
False-positive results could lead to a delay in the correct diagnosis and the initiation of an appropriate treatment for the actual cause of patient illness, which could be another life-threatening disease that is not SARS-CoV-2. False-positive results could also lead to further spread of the SARS-CoV-2 virus when presumed positive patients are grouped into cohorts based on false test results.

Now that Avacta have the SARS -COV-2 Antigen Lateral Flow test available in the EU and with the positive news regarding
AffiDX® antigen lateral flow test detecting the Delta variant of the SARS-CoV-2 virus, it is worth reminding us of what the company set out as customer targets, having up to 60mill as the initial production capacity.
:
Direct sales and distribution partners form Avacta’s routes to market
• Multiple commercial negotiations with distributors and end users ongoing in EU and UK for professional use test.
• Avacta direct sales activity is targeting:
– large corporates for workforce testing;
– work-force testing service providers;
– travel related businesses (airlines, airports);
– events companies;
– care homes and other social and healthcare businesses required to test their employees.
• First distribution partnership now in place with Calibre Scientific:
– Non-exclusive distribution agreement serving EU and UK.
• Avacta remains engaged with the UK government procurement pathway through Porton Down1.
• Other overseas non-EU customers/distributors in discussion.

Data released by the Department of Education shows around 5.1% of all pupils in state-funded schools did not attend school for COVID-19 related reasons on 24 June - a total of 375,000 children.

This is up from 3.3% on 17 June and 1.2% on 10 June.

In primary schools, 4.5% of children did not attend due to virus-related reasons on 24 June, up from 2.7% on 17 June and 1.1% on 10 June.

In total, 24,000 children were off with suspected cases of coronavirus and 15,000 stayed at home after testing positive.

Advertisement
The majority of absentees, 279,000 students, were self-isolating due to potential contact with a COVID-19 case from inside their educational setting.

Avacta’s manufacturing partner’s share price is now up 9%, their trucks are standing by with deliveries

Covid contracts being discussed in House of Parliament and use of emergency contracts!!!

The crisis in our education system and the fact they do not want to loose an academic year!

What is clear, daily tests required to avoid these unnecessary sending home perfectly healthy children Because of a small group of “ positive children “.

http://digitaleditions.telegraph.co.uk/data/646/reader/reader.html?social#!preferred/0/package/646/pub/646/page/2/article/189470

Gene-editing and Gene-therapy stock were flying at the opening after Intella releases breakthrough gene-editing therapy.Stock up 45% with the rest of the sector stocks moving 10-30%.
Very relevant to Avacta?s JV with Daewoong, Affyxcell Therapeutics and it?s pipeline of next generation cell and gene therapies.

FT Saturday
School testing
Opening price 210-15
Pre AGM and more news

Look at Novartis announcement

Look at the Norvatis announcement from the NEJM article regarding radiotherapy.
Ref
Point Biopharma

That is what has been promoted, going forward, daily tests are going to be required in airports, schools etc.
Remember Avacta’s presentation and mentioning conversations with Airlines etc.
Heathrow alone have 80 mill passengers going through the airport, then off course we have all the other airports!
In 2019 European airport traffic was over 1bill passengers!
Going forward, we are facing phenomenal demand and with Avacta producing the world’s most accurate,their current 60mill manufacturing capacity ( UK and non UK ) they as they have pointed out, expanding their capacity substantial

Good closing print at 89!

The Germans are coming and their model with Test Centres near strategic locations, such as Schools, shopping malls, Airports, large companies etc will be duplicated across Europe and they want the best LFT test there is !!!

Once AVA6000 commences phase1 trials( which is about to happen) the majors, Roche, Novartis, AstraZeneca will knocking on the door,wanting to discuss JV with upfront payment, milestone etc
Meanwhile the opposition is now all over Innova story, which a Tory newspaper reminded us of yesterday.
The first Airline order and we are off to the races in a day!!!

And Innova allowed the use of frozen samples

Fauci declares delta variant ‘greatest threat’ to the nation’s efforts to eliminate Covid.
White House chief medical advisor Dr. Anthony Fauci said Tuesday the highly contagious delta variant is the “greatest threat” to the nation’s attempt to eliminate Covid-19.
Delta, first identified in India, now makes up about 20% of all new cases in the United States, up from 10% about two weeks ago, Fauci said during a White House news conference on the pandemic.
He said delta appears to be “following the same pattern” as alpha, the variant first found in the U.K., with infections doubling in the U.S. about every two weeks.
“Similar to the situation in the U.K., the delta variant is currently the greatest threat in the U.S. to our attempt to eliminate Covid-19,” he said.

I suspect All 60,000 needs to be tested, so no one can pass on the the new variant